Literature DB >> 31681687

Mepolizumab as an effective treatment for Kimura's disease associated with ulcerative colitis: A case report.

Faisal Al Shammari1, Abdulrahman Nasiri2, Mohammed Alkhathami2, Fahad Alawfi2, Mohammed Alfifi2, Eqab Al Otaibi2.   

Abstract

Kimura's disease was first described by Kimura and Sceto in China in 1937. Kimura disease is a chronic inflammatory disorder of idiopathic etiology. The clinical presentation of Kimura's disease is painless solitary or multiple subcutaneous nodules, asymmetric, mostly in the head and neck region with often association with lymphadenopathy. Typically, the nodules are found on preauricular, submandibular, and popliteal regions as well as oral cavity, larynx, and parotid glands. In the present report, we describe a case of a 27-year-old male presented to our hospital with history of right neck and lip swelling for 10 days. In the history, the patient mentioned that he had bloody diarrhea four to six times day and he lost 10 kg in 1 month. The specimen was sent for histopathological examination which showed the lymph node architecture is preserved with significant increase number of eosinophils which is consistent with Kimura's disease. There is no agreement on the management aspects in Kimura's disease so far. The primary treatment for Kimura's disease includes surgical resection. Additional medical therapy including regional or systemic steroid therapy, cytotoxic therapy, and radiation has also been utilized. Considered as an inflammatory process, the disease has an excellent prognosis, although it may recur locally and wax and wane over time. Copyright:
© 2019 Journal of Family Medicine and Primary Care.

Entities:  

Keywords:  IBD; Kimura; Saudi Arabia; inflammatory; lung; lymphadenopathy; mepolizumab; rare; ulcerative colitis

Year:  2019        PMID: 31681687      PMCID: PMC6820387          DOI: 10.4103/jfmpc.jfmpc_373_19

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


Introduction

Kimura's disease was first described by Kimura and Sceto in China in 1937. Kimura's disease is a chronic inflammatory disorder of idiopathic etiology. The clinical presentation of Kimura's disease is painless solitary or multiple subcutaneous nodules, asymmetric, mostly in the head and neck region with often association with lymphadenopathy. Typically, the nodules are found on preauricular, submandibular, and popliteal regions as well as oral cavity, larynx, and parotid glands. This case report focused on the discussion, presentation, investigation, and treatment of Kimura's disease.

Patient Information

A 27-year-old Saudi male patient known case of ulcerative colitis diagnosed 8 years ago based on history, clinical presentation, and histological features on mesalamine and prednisolone with poor compliance to medications. The patient presented to our hospital complaining of right neck and lip swelling for 10 days. In the history, the patient mentioned that he had bloody diarrhea four to six times day and he lost 10 kg in 1 month.

Clinical Findings

Clinically, there is a swelling in the right submandibular and anterior cervical lymph nodes. The masses were painless, firm, subcutaneous, nontender measured 2 × 3 cm and 1 × 1 cm, respectively.

Diagnostic Assessment

Biochemical tests showed an eosinophilic count of 23% (EAC: 3200 eosinophils/μL), immunoglobulin E (IgE) 339 g/L (normal <200). Liver and renal functions tests were within normal. Computed tomography (CT) of the neck, chest, abdomen, and pelvis showed multiple homogeneous enhanced significant enlarged lymph nodes seen at both submandibular regions on both sides of the neck [Figure 1]. CT also showed tree in bud pattern in the anterior segment of the right upper lobe and middle lobe of the lung with mild cervical lymphadenopathy [Figure 2].
Figure 1

Axial CT scan of the neck demonstrate enlarged bilateral cervical LN

Figure 2

Axial CT scan of the chest (lung window) shows tree-in-bud appearance

Axial CT scan of the neck demonstrate enlarged bilateral cervical LN Axial CT scan of the chest (lung window) shows tree-in-bud appearance Colonoscopy was performed which showed pancolitis up to the cecum with MAYO score of 2 and random biopsies were taken [Figure 3].
Figure 3

Histopathology of sigmoid colon sample shows chronic active colitis

Histopathology of sigmoid colon sample shows chronic active colitis Cervical lymph node true-cut biopsy was performed [Figure 4]. The specimen was sent for histopathological examination that showed the lymph node architecture is preserved with significant increase number of eosinophils which is consistent with Kimura's disease.
Figure 4

Lymph node architecture is preserved with significant increase number of eosinophils

Lymph node architecture is preserved with significant increase number of eosinophils Bone marrow aspiration and biopsy were performed and reported as there is no evidence of marrow infiltration by malignant lymphoma. With correlation of all these finding diagnoses of Kimura's disease was established.

Therapeutic Intervention

The patient was discharged on prednisolone 40 mg once daily by mouth, for 10 days then tapered down by 5 mg every 2 weeks, azathioprine 75 mg po od, Levocetirizine 5 mg po od, Montelukast 10 mg po od, and discontinue the mesalamine with follow-up in the clinic with CT neck, chest, abdomen, and pelvis after 2 months.

Follow-up and Outcomes

During the follow-up in the clinic the patient developed bloody diarrhea four times per day after stopping of steroid. CT neck, chest, abdomen, and pelvis showed no enlarged lymph nodes in the body and his IgE level was 274 g/L. Azathioprine was increased to 125 mg po od, mesalamine 3 gm po od and anti-immunoglobulin E medications was started, mepolizumab 100 mg SC every 4 weeks. After 2 and 3 months follow-ups, the patient has no bloody diarrhea, no abdominal pain, no neck or lips swelling, and his weight was increased by 2 kg. Clinical exam for head and neck lymph nodes was negative for lymphadenopathy. CT neck, chest, abdomen, and pelvis again showed no enlarged lymph nodes in the body.

Discussion

Kimura's disease was first described by Kimura and Sceto in China in 1937.[1] Kimura's disease is a chronic inflammatory disorder of idiopathic etiology that presents as painless lymphadenopathy or subcutaneous masses in the head and neck region.[2] The etiology remains unknown; however, an allergic or autoimmune reaction to an unknown stimulus, or a viral or parasitic or infection, which would alter T lymphocyte regulation or induce a type I immunoallergic reaction have been proposed.[34] Kimura's disease generally not only affects Asian men, but also non-Asians were frequently reported in the literature.[2567] Controversy has existed in the literature regarding whether angiolymphoid hyperplasia with eosinophilia (ALHE) and Kimura's disease are the same entity. However, the two conditions can distinguish based on clinical and histopathologic characteristics.[57] The clinical presentation of Kimura's disease is painless solitary or multiple subcutaneous nodules, asymmetric, mostly in the head and neck region with often association with lymphadenopathy. Typically, the nodules are found on preauricular, submandibular, and popliteal regions as well as oral cavity, larynx, and parotid glands.[235] They are rarely reported in other localizations like eyelids, lacrimal glands, orbit, axilla, groin, forearm, and kidneys.[189] The differential diagnosis includes malignant disorder (acute lymphocytic leukemia, T-cell lymphoma, Kaposi sarcoma, Hodgkin's lymphoma, or parotid tumor), ALHE, Langerhans cell histiocytosis, florid follicular hyperplasia, and Castleman disease. Kimura's disease may be easily mistaken for a malignant disorder because of a mass localized in the parotid gland and associating with lymphadenopathy.[310111213] Histologically, Kimura's disease comprised preserved lymph node architecture with reactive and florid germinal centers. Eosinophilic infiltration, lysis of the follicles, and occasionally microabscesses vascular proliferation are also present.[251415] The pathogenesis of Kimura's disease and ulcerative colitis is yet unknown. However, the development of these disorders may involve a systemic immune disorder.[616] There is no agreement on the management aspects in Kimura's disease so far. The primary treatment for Kimura disease includes surgical resection. Additional medical therapy including regional or systemic steroid therapy, cytotoxic therapy, and radiation has also been utilized. Considered as an inflammatory process, the disease has an excellent prognosis, although it may recur locally and wax and wane over time.[11171819]

Patient Perspective

Informed Consent: Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  17 in total

1.  Bilateral lacrimal gland involvement with Kimura disease in an African American male.

Authors:  Pradeepa Yoganathan; Dale R Meyer; Martha G Farber
Journal:  Arch Ophthalmol       Date:  2004-06

2.  Kimura's disease in a Caucasian male treated with cyclosporine.

Authors:  Ahu Birol; Onder Bozdogan; Hatice Keleş; Mustafa Kazkayasi; Yeter Bagci; Simay Kara; Mukadder Koçak; Ahu Birol
Journal:  Int J Dermatol       Date:  2005-12       Impact factor: 2.736

Review 3.  Kimura disease: review of the literature.

Authors:  Q-F Sun; D-Z Xu; S-H Pan; J-G Ding; Z-Q Xue; C-S Miao; G-J Cao; D-J Jin
Journal:  Intern Med J       Date:  2008-08       Impact factor: 2.048

4.  Comparison of the efficacy of different treatment modalities for Kimura's disease.

Authors:  P Ye; D-Q Ma; G-Y Yu; Y Gao; X Peng
Journal:  Int J Oral Maxillofac Surg       Date:  2016-09-07       Impact factor: 2.789

5.  Successful treatment of Kimura's disease with leflunomide and methylprednisolone: a case report.

Authors:  Xiao-Rong Ma; Shu-Jia Xin; Tian-Xiang Ouyang; Yue-Ting Ma; Wei-Ying Chen; Meng-Ling Chang
Journal:  Int J Clin Exp Med       Date:  2014-08-15

6.  Kimura's disease: A diagnostic challenge experienced with cytology of postauricular swelling with histopathological relevance.

Authors:  Mingma Sherpa; Rachna Lamichaney; Asitava Deb Roy
Journal:  J Cytol       Date:  2016 Oct-Dec       Impact factor: 1.000

7.  A rare case of inguinal kimura disease.

Authors:  X Gregory; N I Soon; R Nur Aklina
Journal:  Med J Malaysia       Date:  2018-10

8.  Angiolymphoid hyperplasia with eosinophilia and vascular tumors of the head and neck.

Authors:  D M Don; A Ishiyama; A K Johnstone; Y S Fu; E Abemayor
Journal:  Am J Otolaryngol       Date:  1996 Jul-Aug       Impact factor: 1.808

9.  Kimura's disease: risk factors of recurrence and prognosis.

Authors:  Qing-Li Chen; Srijana Dwa; Zhong-Cheng Gong; Keremu Abasi; Bin Ling; Hui Liu; Lu-Lu Hu; Bo Shao; Zhao-Quan Lin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  Kimura's Disease: A Rare Cause of Nephrotic Syndrome with Lymphadenopathy.

Authors:  Siti Kamariah Othman; Kamaliah Mohd Daud; Nor Hayati Othman
Journal:  Malays J Med Sci       Date:  2011-10
View more
  2 in total

1.  Efficacy of faecal microbiota transplantation on ulcerative colitis and its effect on gastrointestinal motility and immune function.

Authors:  Dengshun Lei; Hong Xu; Renqun Peng; Mei Yang; Xinghui Li; Wei Zuo; Juhua Gou; Shuangjiang Yu; Min Huang; Hao Liu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

Authors:  Ian D Pavord; Elisabeth H Bel; Arnaud Bourdin; Robert Chan; Joseph K Han; Oliver N Keene; Mark C Liu; Neil Martin; Alberto Papi; Florence Roufosse; Jonathan Steinfeld; Michael E Wechsler; Steven W Yancey
Journal:  Allergy       Date:  2021-09-16       Impact factor: 14.710

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.